AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 62 min read$NTRA

Chapman Steven Leonard sold $774K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 3,409 shares of Natera, Inc. (NTRA) at $226.97 ($0.77M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates the insider activity record but does not, by itself, provide new business performance or forward-looking guidance.

02

Market read

Primarily sentiment/positioning noise; limited fundamental read-through due to 10b5-1 pre-arrangement.

03

What to watch

Traders may overweight insider selling; the key mitigating detail is the pre-arranged 10b5-1 plan, which often reduces signal strength.

Relevance 6/10Novelty 3/10Timing: Filed June 5 for a June 4 sale; disclosure may affect intraday sentiment.

Background

SEC Form 4 insider transaction: CEO/president Chapman Steven Leonard sold 3,409 NTRA shares at ~$226.97 on June 4, with a stated 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and President Chapman Steven Leonard sold $773.7K of NTRA shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Near-term price reaction likely muted; any move would be more sentiment/positioning-driven than fundamentals.

Evidence & confidence

The filing is a routine insider transaction disclosure and explicitly references a pre-arranged 10b5-1 plan, reducing interpretability as new negative information.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated operational/regulatory/clinical catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • issuer
    Natera, Inc.

    Subject of the Form 4 insider sale by its CEO/president under a 10b5-1 plan.

  • insider
    Chapman Steven Leonard

    CEO and President who executed the open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

SEP 9
$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

yahoo.com2 min
SEP 2
$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

etfdb.com3 min
AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min